The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.
Pavo, Noemi
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients. [electronic resource] - Scientific reports 02 2019 - 2554 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
2045-2322
10.1038/s41598-019-38867-2 doi
Adult
Aged
Biomarkers--blood
Female
Humans
Male
Middle Aged
Myelodysplastic-Myeloproliferative Diseases--diagnosis
Neoplasms--diagnosis
Neprilysin--blood
Prognosis
Survival Analysis
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients. [electronic resource] - Scientific reports 02 2019 - 2554 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
2045-2322
10.1038/s41598-019-38867-2 doi
Adult
Aged
Biomarkers--blood
Female
Humans
Male
Middle Aged
Myelodysplastic-Myeloproliferative Diseases--diagnosis
Neoplasms--diagnosis
Neprilysin--blood
Prognosis
Survival Analysis